Skip to main content
. 2021 Sep 1;13(9):e14332. doi: 10.15252/emmm.202114332

Figure EV1. Analysis of N‐glycans from whole serum glycoproteins.

Figure EV1

To investigate the general hypofucosylation in the patient, released serum N‐glycans were measured by xCGE‐LIF. (Data were obtained from serum; n = 10 for controls; experiment was independently repeated two times).
  1. Change of relative N‐glycan composition. While the patient's distribution of hybrid‐, high‐mannose and complex type N‐glycan was not altered, a marked reduction of core‐ and antenna‐fucosylated structures was detected in comparison to the controls.
  2. Unique glycans. Several unique glycans were identified either in the control pool as well as in the patient‐derived serum. Whether one of them can serve as biomarker for GFUS‐CDG needs to be determined.

Data information: N‐glycan structures were produced using Glycan Builder 2 (Tsuchiya et al, 2017) following the Symbol Nomenclature for Glycans (SNFG) guidelines (Neelamegham et al, 2019). Naming of N‐glycan structures was adapted from the Oxford nomenclature (Doherty et al, 2018).